期刊
ANNALS OF NEUROLOGY
卷 57, 期 2, 页码 197-203出版社
WILEY-LISS
DOI: 10.1002/ana.20361
关键词
-
资金
- NINDS NIH HHS [U01NS043127, U01NS43128] Funding Source: Medline
Futility studies are designed to test new treatments over a short period in a small number of subjects to determine if those treatments are worthy of larger and longer term studies, or if they should be abandoned. An appropriate outcome measure for a neuroprotection futility study in Parkinson's disease (sensitive to tracking disease progression in the short-term) has not been determined. Data sets from three clinical trials were used to compare Parkinsons disease outcome measures. Total Unified Parkinson's Disease Rating Scale (UPDRS; Mentation + Activities of Daily Living + Motor) change and Motor plus Activities of Daily Living UPDRS change, measured in untreated patients, required the smallest sample sizes of all the outcome measures explored. Other outcomes (UPDRS Motor, UPDRS Activities of Daily Living, and time to need levodopa) required somewhat larger sample sizes. Futility designs in Parkinsons disease are feasible in terms of short duration. and small sample size requirements, and this design is being applied in two ongoing 14 Parkinson's disease studies to select agents for future larger and longer term neuroprotection studies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据